Prostate cancer (PCa) is the 2nd most common malignancy in males and the leading cause of cancer-related deaths among men. In recent years, novel therapies have emerged for metastatic castration-resistant prostate cancer (mCRPC) including immunotherapy, androgen-receptor signaling inhibitors, and radio-nuclide therapies. DNA Damage Repair (DDR) genes are frequently mutated in advance PCa and are useful biomarkers for targeted therapy such as poly-ADP ribose polymerase (PARP) inhibitors. DDR gene defects may affect tissue radio-sensitivity and could serve as biomarkers for therapy with alpha and beta-emitting radionuclides. Preliminary clinical reports suggest a potential trend toward longer survival in DDR+ subjects when treated with α-emitters, however, survival benefit was not significant in patients treated with β-emitting radionuclides. A comprehensive study regarding the impact of DDR genes in prostate cancer patients treated with alpha emitters is vital.
Key words: Prostate Cancer, Radionuclide, Genomics, Therapy, DDR.
|
